#ACR21 plenary#1424. JUNIPERA study for Secukinumab for ERA, JPsA ⭐️Time to disease flare longer in SEC vs PBO ⭐️Sustained improvement up to wk 104 ▶️Rapid decrease of JADAS-27 in initial open-label portion of study https://t.co/m5bl9Ho163 @Rheumnow https://t.co/wnEdxeYfjh

• https://bit.ly/3bPbT7t

Network meta-analysis assessed comparative risk of respiratory tract infection (RTI) with different b/ts DMARD in PsA ⭐️Abatacept 🔽likelihood RTIs compared ADM/ apremilast/ CTZ/ GOL/TOF ⭐️Apremilast 🔼likelihood RTIs compared INX /secukinumab Abst # 1359 #ACR21 @RheumNow

Abst1305 #acr21 @RheumNow undiagnosed depression in AxSpA: 9.9% pts w/abnormal HADs-D scores,23.9% moderate to severe PHQ-9 scores. F had higher mean HADs-D scores than M, w/abnormal scores in 19% of F & 6% M. significantly worse BASDAI&AQoL scores in axSpA pts w/abnormal HADs-D https://t.co/sPkGPcITCs

Knee OA novel measure of structure and function - Quantitative radiographic OA scores (QROS) software that measures medial minimum joint space width (mJSW) and other measures in the tibiofemoral compartment predicts time to TKA. Model well calibrated @rheumnow #ACR21 #abst1051 https://t.co/9LKlb7bZO0

Characteristics of #uveitis w/axSpA seen in patients of this study: 👁‍🗨14.6%➡uveitis 👁‍🗨All acute, anterior & 93% unilateral 👁‍🗨Delay in dx & ⬆ HLAB27+ No diff. in TNFi use Consistent fact: Uveitis is the ⬆ common extra-articular manifestation in axSPA @RheumNow #ACR21 abs1324 https://t.co/6qC8RxxBrM

Study comparing TNFi vs SEC in PsA pts w/ active US confirmed enthesitis finds superiority of TNFi (ADA, CTZ, ETN) in regards to active entheseal disease. Abs 1356 #ACR21 #RheumNow @RheumNow https://t.co/BvZZsTP3Ta https://t.co/G5cWrQgqDC

• Effects of TNF-α versus Secukinumab on Active Ultrasound Confirmed Enthesitis i…

#ACR21 Abs#1425. AURORA2 - voclosporin for LN extension ⭐️216/357 pts continued into 2-yr study ⭐️Mean UPCR at month 30: 0.58 in VOC vs 1.3 control. eGFR ⬇️ in VOC, remains stable ⭐️No new AEs @Rheumnow https://t.co/m5bl9Ho163 https://t.co/VVGOCd9vmC

• https://bit.ly/3bPbT7t

What better than a tweet on a #ACR21 study of tweets! 😂 Using Twitter Firehose data stream - yes we should do a study just during the ACR week...! Fake tweets exists but low in the rheumatology community! @rheumnow #abst1068 Paper - https://t.co/ekguL5qXen https://t.co/rfy7vZlXOn

• Analysis of Tweets Containing Information Related to Rheumatological Diseases o…

Abst1356 #acr21 @RheumNow TNFi vs SEC in active US confirmed enthesitis: mean ActiveMASEI score ⬇️ 4.37 w/TNFi vs 2.22 secukinumab (p = 0.030). Secucinumab leads in regards to the PASI & DLQI score with Sec vs TNFi ( 3.44 vs 1.03 p = 0.001 & 5.57 vs 1.35 p = 0.005 respectively https://t.co/fGTxzvGY99

FDA Safety Update - Questions for Dr. Nikolov, Habal, Golding, Rajpal - Do we need post marketing RCTs BARI and UPA: one in prog for BARI, not for UPA - 1133, why high CI of 1.8? Based on stricter margins based on prior studies with diabetes - Are Tyk2 a worry? to early -#ACR21

FDA Safety Update - Questions for Dr. Nikolov, Habal, Golding, Rajpal - Bari OK in COVID but now CV risk: theres a limit (14d) for Bari in COVID - CV Risk applied to all JAKi - largely because all have same indication, same populations at risk #ACR21

FDA update - the safety of XIAFLEX injections (collagenase for Dupytrens) under review #ACR21 https://t.co/KOP3P8ASqN

Excellent Rheum Pearls session w/ Drs. Kolfenbach & Stone: 🔘⬆️CRP in SLE:: think infection not flare 🔘Ferritin:ESR ratio differentiate JIA flares from MAS 🔘Dilated capillaries at eyelid margin in JDM = disease activity 🔘Auscultate Back for bruits in TAK #ACR21 https://t.co/3pUOhYR3L2